By SPC News Staff
The FDA granted accelerated approval to pembrolizumab (Keytruda, Merck) to treat adults and children with primary mediastinal large B-cell lymphoma (PMBCL) that is refractory or has relapsed after two or more prior lines of therapy and for women with recurrent or metastatic cervical cancer that progresses on or after chemotherapy and whose tumors express programmed death ligand-1 (PD-L1).
Pembrolizumab is not recommended for the treatment of patients with PMBCL who require